India, Nov. 16 -- Zealand Pharma A/S (ZEAL.CO), a biotechnology company, received a marketing authorization from the European Commission (EC) for Zeydovio in the treatment of short bowel syndrome.
The drug is now approved for sale in all territories of the European Union (EU).
Short bowel syndrome (SBS) is a rare chronic condition causing the reduced or complete loss of intestinal function. Afflicted patients are often left with a lifetime dependency on complex parenteral support (PS) and remain at risk for a number of systemic complications.
Zeydovio (glepaglutide) is a long-acting GLP-2 analog that shows an extended half-life and high stability in an aqueous solution. The drug is administered twice a week via a ready-to-use, single-dos...